Exploratory subgroup analyses of EV-302 : a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

Bron
ESMO Open - ISSN 2059-7029-10:8 (2025) p. 1-9
Auteur(s)
    M.S. van der Heijden, T. Powles, S. Gupta, Y. Loriot, M.D. Galsky, B.P. Valderrama, S.S. Sridhar, E.Y. Yu, G. Iyer, E. Kikuchi, D. Castellano, J. Hoffman-Censits, A. Drakaki, N. Mar, J.P. Maroto Rey, Christof Vulsteke, W. Arafat, I. Duran, N.A. Dawson, U. Swami, S. Gorla, B.H. Moreno, X. Yu, Y.-T. Lu, J. Bedke

Delayed FLAIR-enhancement of benign notochordal remnant (ecchordosis physaliphora)

Bron
The Neuroradiology Journal - ISSN 1971-4009-38:2 (2025) p. 220-223
Auteur(s)
    Jeroen Peels, Christof Vulsteke, Michael Boedts, Eline Marin, Laurens J.L. De Cocker

The unjustified fear of erdafitinib-induced central serous retinopathy

Bron
Annals of oncology - ISSN 0923-7534-36:8 (2025) p. 1001-1002
Auteur(s)

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors : should we treat beyond two years?

Bron
Acta oncologica - ISSN 0284-186X-64 (2025) p. 979-988
Auteur(s)
    Alexander Decruyenaere, Christine Gennigens, Sylvie Rottey, Annouschka Laenen, Emmanuel Seront, Els Everaert, Philip R. Debruyne, Heidi van den Bulck, Julie Bastin, Annelies Verbiest, Christof Vulsteke, Peter Schatteman, Daisy Luyten, Sandrine Aspeslagh, Nieves Martinez-Chanza, Marlies De Bock, Thomas Meyskens, Jolanda Verheezen, Barbara Brouwers, Benoit Beuselinck

Sacituzumab govitecan in advanced urothelial carcinoma : TROPiCS-04, a phase III randomized trial

Bron
Annals of oncology - ISSN 0923-7534-36:5 (2025) p. 561-571
Auteur(s)
    T. Powles, S. Tagawa, Christof Vulsteke, M. Gross-Goupil, S.H. Park, A. Necchi, M. De Santis, I. Duran, R. Morales-Barrera, J. Guo, C.N. Sternberg, J. Bellmunt, P.J. Goebell, M. Kovalenko, F. Boateng, M. Sierecki, L. Wang, C.S. Sima, J. Waldes, Y. Loriot, P. Grivas